Q-omics provides the consensus-scored ANXA5 profile across patient tissues and cancer cell-line models. ANXA5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ANXA5 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ANXA5 RNA expression shows 19,580 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, HNSC, and UVM as cancer lineages where ANXA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANXA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANXA5 survival associations across molecular data types. ANXA5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANXA5 RNA expression–survival associations across cancer types. High ANXA5 expression shows unfavorable associations in STAD, BLCA, LIHC, HNSC and LGG, but favorable associations in UCEC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for ANXA5 RNA expression.
This table summarizes ANXA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ANXA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANXA5 shows lower tumor expression in LUSC and LUAD and higher tumor expression in HNSC, KIRC, COAD and KIRP. The HNSC box plot shows higher ANXA5 RNA expression in tumor versus normal tissue (log2 FC = +1.645, t-test p < 0.001).
This table shows molecular features associated with ANXA5 in patient tissues and cancer cell lines. In patient samples, ANXA5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANXA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
